apraglutide vs teduglutide (Gattex)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Short Bowel Syndrome
Shared mechanism: GLP-2 receptor · full Short Bowel Syndrome pipeline
apraglutide
Developed by Ironwood Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT05018286 (registry estimate)
No aligned efficacy figure on record for this race.
teduglutide (Gattex)
Marketed by Takeda Pharmaceutical Company
NCT00798967 · Phase 3 · completed
The trial was randomized, quadruple-blind, and placebo-controlled, with 43 participants per group, and its clinical primary endpoint was met (p=0.002). However, the available record does not report the power or sample-size calculation needed to verify that the study was adequately powered, so the evidence is graded moderate rather than strong.
Next expected readout: January 2027 · NCT07400783 (registry estimate)
Reported efficacy
Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): 0.025 mg/kg/Day Teduglutide — Participant Diary: 13 Participants; Investigator Prescribed: 13 Participants | 0.05 mg/kg/Day Teduglutide — Participant Diary: 18 Participants; Investigator Prescribed: 18 Participants | Standard of Care — Participant Diary: 1 Participants; Investigator Prescribed: 2 Participants (unclear)
Result source: NCT02682381
Results for Short Bowel Syndrome
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
apraglutide: no structured comparison results are available for Short Bowel Syndrome.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: apraglutide's landscape · teduglutide (Gattex)'s landscape